Compare CZWI & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CZWI | DTIL |
|---|---|---|
| Founded | 1938 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 201.8M | 197.9M |
| IPO Year | 2006 | 2019 |
| Metric | CZWI | DTIL |
|---|---|---|
| Price | $21.27 | $6.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $45.00 |
| AVG Volume (30 Days) | 39.8K | ★ 228.6K |
| Earning Date | 04-27-2026 | 05-14-2026 |
| Dividend Yield | ★ 2.02% | N/A |
| EPS Growth | ★ 8.96 | N/A |
| EPS | ★ 0.50 | N/A |
| Revenue | N/A | ★ $1,070,000,000.00 |
| Revenue This Year | $13.02 | N/A |
| Revenue Next Year | $9.42 | N/A |
| P/E Ratio | $42.46 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.61 | $3.53 |
| 52 Week High | $24.43 | $9.62 |
| Indicator | CZWI | DTIL |
|---|---|---|
| Relative Strength Index (RSI) | 44.69 | 35.63 |
| Support Level | $20.14 | $6.02 |
| Resistance Level | $21.63 | $7.92 |
| Average True Range (ATR) | 0.68 | 0.40 |
| MACD | -0.03 | -0.07 |
| Stochastic Oscillator | 7.97 | 1.62 |
Citizens Community Bancorp Inc is a bank holding company that offers traditional community banking services to businesses, Agricultural operators, and consumers, including one-to-four-family residential mortgages. it also offers a variety of loan products including commercial real estate loans, commercial and industrial (C&I) loans, agricultural real estate loans, agricultural operating loans, residential mortgages, home equity lines-of-credit, and consumer loans and offers deposit products through its branches, including demand deposits, various savings and money-market accounts and certificates of deposit. The company's sources of funds are deposits; amortization, prepayments, and maturities of outstanding loans; other short - term investments; and funds provided from operations.
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).